-

Myomo, Inc. Announces Participation in Three September Investment Conferences

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul Gudonis, Myomo’s chairman and chief executive officer, and David Henry, Myomo’s chief financial officer, will participate in three investment conferences in September. They are:

  • 2021 Colliers Institutional Investor Conference, which will be held virtually, on Thursday, September 9, 2021. This conference’s format is 1x1 meetings with institutional investors.
  • H.C. Wainwright 23rd Annual Global Investment Conference, which will be held virtually from September 13-15, 2021. Investors interested in participating should contact H.C. Wainwright directly or register here.
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which will be held virtually September 20-23, 2021. Management’s presentation may be accessed beginning at 12:25 p.m. ET on September 21 at this link, which will also be available for a period of time in the investor relations section of the Company’s website.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Contacts

For Myomo:
ir@myomo.com

Investor Relations:
Kim Sutton Golodetz
LHA Investor Relations
kgolodetz@lhai.com
212-838-3777

Myomo, Inc.

NYSEAM:MYO

Release Versions

Contacts

For Myomo:
ir@myomo.com

Investor Relations:
Kim Sutton Golodetz
LHA Investor Relations
kgolodetz@lhai.com
212-838-3777

More News From Myomo, Inc.

Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. “We delivered 2025 revenue at the midpoint of our updated guidance range with record fourth quarter revenues from the U.S. orthotics and prosthetics ("O&P") and Int...

Myomo and Elevance Health Agree to Contract for Multi-State Network Participation

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become eff...

Myomo to Report Fourth Quarter 2025 Financial Results on March 9

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business upd...
Back to Newsroom